150
Participants
Start Date
April 20, 2017
Primary Completion Date
September 30, 2025
Study Completion Date
April 30, 2026
Etoposide
"BEAM: 100 mg/m\^2 IV over 2 hours BID on Days -5, -4, -3, -2 \
BCNU
BEAM \& CBV: 300 mg/m\^2 IV over over 2 hours on Day -6
AraC
BEAM: 100 mg/m\^2 IV over 1 hour BID on Days -5, -4, -3, -2
Melphalan
BEAM: 140 mg/m\^2 IV over 20 minutes on Day -1
Peripheral blood stem cell transplantation
All Arms: Day 0 infuse PBSC. All patients will have PBSC collected by leukapheresis. Mobilization will be done with G-CSF.
G-CSF
All patients should receive G-CSF, 5 ug/kg/day IV as a bolus injection each evening beginning on day +5 until the ANC is \>2500 x 10\^9/L for 2 consecutive days. G-CSF will subsequently be restarted at 5 ug/kg/day SC or IV if the ANC falls below 1000/mm\^3
Cyclophosphamide
"CBV: 1.5 gm/M\^2 over 2 hours at 10 a.m. on Days -6, -5, -4, -3 \
Total Body Irradiation
CY/TBI: 165 cGy bid on Day -4, -3, -2, -1
RECRUITING
Masonic Cancer Center, University of Minnesota, Minneapolis
Masonic Cancer Center, University of Minnesota
OTHER